

3 out of 4

People with HCV are recorded as engaged in care.



Once engaged,
90%
initiate
treatment.

HCV mortality and morbidity in
the UK has

reduced since 2015



likely as a result of
increased access
to DAAs.

93,000 people in the UK
were living with chronic HCV
in 2021.

(modelled estimates)

This is a **49%** reduction from 2015.

At the current rate of decline in prevalence, the
UK should meet the

WHO elimination target
by 2030.

However, less than **half** of people who
inject drugs who have ever had HCV are
aware of their diagnosis.



Provision of

needles and syringes

(NSP)

remains a challenge

and has been impacted by the
COVID-19 pandemic...



...This impacts **new** infections and
reinfections.

Around **4%**

of people
who have been treated for HCV
have a **re-infection.**

